Novartis vs Pharmaron Biologics: CDMO Comparison
How does Novartis compare to Pharmaron Biologics for Gene Therapy manufacturing?
Side-by-side comparison of Novartis and Pharmaron Biologics on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Novartis has more FDA inspections on record (15 vs 3) — a deeper regulatory paper trail.
- Pharmaron Biologics carries a cleaner inspection mix — no OAI classifications versus 2 for Novartis.
- Novartis holds 59 active EMA GMP certificates; Pharmaron Biologics does not appear in EudraGMDP.
- Novartis maintains 3 MHRA / UK GMP certificates; Pharmaron Biologics does not.
- Novartis appears as a manufacturing partner on more matched clinical programs (137 vs 0) — a broader sponsor book.
On a 13-modality CDMO landscape, both Novartis and Pharmaron Biologics qualify as Gene Therapy manufacturers; Novartis carries the higher composite Signal Score for Gene Therapy programs in this comparison.
What to evaluate for Gene Therapy programs
Both Novartis and Pharmaron Biologics qualify as Gene Therapy CDMOs. When choosing between them for Gene Therapy programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Vector platform match
The first shortlist filter for any gene therapy program is vector platform. AAV for in vivo systemic; lentiviral for ex vivo cell engineering; adenoviral for vaccines and select high-expression programs. Filter by platform first, then compare within the platform.
Regulatory record on-platform
A CDMO with a strong FDA record on AAV manufacturing doesn't automatically de-risk lentiviral work — inspections are facility- and process-specific. Verify the inspection record on the exact platform and site your program will use.
Capacity match to phase
Early clinical AAV runs at 50-200L; commercial can reach 1000-2000L single-batch. Lentiviral commercial supply is a much narrower field. Confirm the CDMO's capacity headroom at your target phase before shortlisting.
Analytics maturity
Vector analytics — capsid ratio, titer, potency, RCL for lentivirus — drive lot release. A CDMO with qualified, established assays de-risks comparability and tech transfer.
Frequently asked: Novartis vs Pharmaron Biologics
How does Novartis compare to Pharmaron Biologics for Gene Therapy manufacturing?
On CDMO Signal's composite Signal Score, Novartis is 88/100 and Pharmaron Biologics is 87/100; Novartis has 15 FDA inspections on record vs 3 for Pharmaron Biologics; European coverage is 62 active EMA+MHRA certificates for Novartis vs 0 for Pharmaron Biologics. Both are tracked in the CDMO Signal directory as Gene Therapy CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Novartis or Pharmaron Biologics?
Novartis has 15 FDA inspections on record (NAI 6 / VAI 7 / OAI 2) and 0 warning letters. Pharmaron Biologics has 3 FDA inspections on record (NAI 3 / VAI 0 / OAI 0) and 0 warning letters.
How do Novartis and Pharmaron Biologics compare on European GMP coverage?
Novartis holds 59 active EMA GMP certificates and 3 MHRA / UK certificates. Pharmaron Biologics holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — Novartis or Pharmaron Biologics?
Novartis is matched to 137 ClinicalTrials.gov records as a manufacturing partner; Pharmaron Biologics is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for Gene Therapy manufacturing — Novartis or Pharmaron Biologics?
Both Novartis and Pharmaron Biologics are tagged as Gene Therapy CDMOs in our directory, so both are credible options for Gene Therapy programs. The most important differentiator for Gene Therapy selection is typically vector platform match: The first shortlist filter for any gene therapy program is vector platform. AAV for in vivo systemic; lentiviral for ex vivo cell engineering; adenoviral for vaccines and select high-expression programs. Filter by platform first, then compare within the platform. Review each CDMO's profile and inspection record before shortlisting.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →